SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

RAGE GUY (RAGE) is a cryptocurrency inspired by the Rage Guy meme, one of the earliest and most recognizable characters from internet rage comics. The project captures the cultural legacy of early meme history and brings it onto the blockchain in tokenized form. It is designed as a community-driven digital asset that celebrates internet culture, nostalgia, and the role memes play in shaping online communities.

Rage Guy

RAGE CRYPTO is surging in conversation driven by its fiercely dedicated "Rage Bros" community, which exhibits "delusional & retarded" conviction and relentless "bagworking" to position this OG meme coin on Solana for a future "51B" valuation. This active community believes it's building a foundational project that will lead the next meme bull run.

ZIM Integrated Shipping Services Ltd. engages in the provision of shipping and logistics services. It offers shipping solutions, including the transportation of out-of-gauge cargo, refrigerated cargo, and dangerous and hazardous cargo. The company was founded on June 7, 1945 and is headquartered in Haifa, Israel.

Zim Integrated Shipping Services Ltd

ZIM Integrated Shipping Services is trending amid reports of competing takeover bids from major shipping firms like MSC and Hapag-Lloyd, following the board's rejection of an internal management-led buyout for significantly undervaluing the company. The community is actively speculating on a final acquisition price well above current levels, citing the company's robust asset value and the potential for special dividends, while also debating the impact of rising container freight rates and governmental approvals.

Eastman Kodak Co. engages in the provision of analog and digital innovations. It operates through the following segments: Traditional Printing, Digital Printing, Advanced Materials and Chemicals, and Brand. The Traditional Printing segment consists of Prepress Solutions, which includes Kodak's digital offset plate offerings and computer-to-plate imaging solutions. The Digital Printing segment contains Electrophotographic Printing Solutions, Prosper, Versamark and Software. The Advanced Materials and Chemicals segment consists of four lines of business: Industrial Film and Chemicals, Motion Picture, Advanced Materials and Functional Printing, and Kodak Services for Business (KSB). The Brand segment includes licensing of the Kodak brand to third parties. The company was founded by George Eastman in 1880 and is headquartered in Rochester, NY.

Eastman Kodak Co.

Eastman Kodak is trending due to its recent expansion into U.S.-made pharmaceutical products, sparking community discussion and high anticipation for significant government contracts focused on national security for domestic drug supply chains, alongside its ongoing pivot into advanced battery materials.

Ventyx Biosciences, Inc. engages in developing novel small molecule therapeutics for the treatment of autoimmune diseases. Its clinical stage pipeline includes VTX958, a Phase 1 allosteric TYK2 inhibitor for the treatment of a broad range of autoimmune diseases, VTX002, a Phase 2-ready S1P1 receptor modulator for the treatment of ulcerative colitis, and VTX2735, a Phase 1-ready peripheral inhibitor of the NLRP3 inflammasome, which is a mediator of multiple inflammatory conditions. The company was founded by Raju S. Mohan on November 21, 2018 and is headquartered in San Diego, CA.

Ventyx Biosciences Inc

Ventyx Biosciences is actively discussed following Eli Lilly's $1.2 billion acquisition offer, as the community anticipates a bidding war for its advanced NLRP3 inhibitor pipeline, which boasts compelling cardiovascular and neuro-inflammatory data and significant synergistic potential with GLP-1 agonists.

Macy's, Inc. engages in the retail of apparel, accessories, cosmetics, home furnishings, and other consumer goods. The firm's brands include Macy's, Bloomingdale's, and Bluemercury. It offers men's, women's, and children's apparel, women's accessories, intimate apparel, shoes, cosmetics, fragrances, as well as home and miscellaneous products. The company was founded by Rowland H. Macy in 1858 and is headquartered in New York, NY.

Macy`s Inc

Macy's Inc

Macy's is trending after reporting stronger-than-anticipated earnings and boosting its financial outlook, with its 'Bold New Chapter' strategy showing positive comparable sales growth, especially in luxury segments. The community is split, with many bullish on the turnaround and potential for further upside, while others voice caution over a conservative holiday forecast and broader retail sector challenges.

Helium is a decentralized machine network powered by a physical blockchain. The network is created by gateways who also double as miners on our network. These gateway operators can earn tokens based on coverage they provide as well as transaction fees gained from machines connecting to their gateway  Helium is a new cryptocurrency. Hotspots earn for providing and validating wireless coverage and when devices on the network connect to the internet through Hospots  Helium is mined and distributed to Hotspot Owners, Helium Inc, and investors. There is no pre-mine of Helium, and every month approximately 5,000,000 new Helium are minted.  At the end of each mining period, roughly every 30 to 60 mins, Helium is distributed according to the allocation shown:

Helium

Helium is actively discussed following recent regulatory clarity and a new AT&T partnership, with the community closely watching its consolidating tokenomics as rewards shift to HNT, reinforcing its position within the growing DePIN sector.

Wave Life Sciences Ltd. is a clinical-stage biotechnology company, which focuses on developing its proprietary RNA medicines platform and PRISM. It also develop and commercialize a pipeline RNA medicines in a variety of therapeutic areas. The company was founded by Gregory L. Verdine and Takeshi Wada on July 23, 2012 and is headquartered in Singapore.

Wave Life Sciences Ltd.

Wave Life Sciences Ltd

Wave Life Sciences (WVE) is trending due to promising interim Phase 1 data for its obesity drug candidate, WVE-007, which demonstrated significant fat loss with muscle preservation and the potential for convenient once or twice-yearly dosing, distinguishing it from existing GLP-1 treatments. This differentiated profile is generating considerable buzz and analyst upgrades, positioning WVE as a key player in the rapidly expanding and competitive obesity market where major pharmaceutical companies are actively seeking next-generation therapies.

VanEck ETF Trust - VanEck Semiconductor ETF

VanEck Semiconductor ETF

The VanEck Semiconductor ETF ($SMH) is experiencing significant discussion as positive analyst commentary and strong earnings from its core holdings propel the sector to new highs, fueling a community debate between sustained AI-driven growth and concerns over its "parabolic" valuation. Bullish options plays indicate some anticipate continued upside, contrasting with calls for an imminent pullback and sector rotation.

Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.

Ocular Therapeutix Inc

Ocular Therapeutix is seeing heightened interest ahead of its upcoming SOL-1 Phase 3 wet AMD trial data release, with community optimism fueled by recent institutional buying, a new high-profile Chief Commercial Officer hire, and the early announcement, all signaling confidence for strong results and potential upside.

Ethereum Classic

Ethereum Classic is trending with highly polarized community sentiment, as many are frustrated by its prolonged decline while others actively accumulate, expecting a significant rebound during an anticipated "altcoin season" fueled by broader crypto market liquidity and regulatory developments.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Nyxoah (NASDAQ:NYXH) Trading Down 2.9% - Here's What Happened

Nyxoah (NASDAQ:NYXH) Shares Down 2.9% - Should You Sell...

Nyxoah Gains Favorable CMS Reimbursement Ruling for Genio System

Nyxoah secures a finalized CMS rule that sharply lifts 2026 reimbursement for Genio implants, opening fresh momentum for its OSA therapy.

<ul class="summary-bullets"><li>Under the new rule, Hospital Outpatient Department (HOPD) reimbursement for Nyxoah’s Genio hypoglossal nerve stimulation implants will increase to approximately $45,000 starting in 2026.</li><li>According to Nyxoah, the Genio procedure is well-suited for the ASC environment, and the new rules create new opportunities for site-of-service diversification as well.</li></ul><p>Shares of Nyxoah SA (NYXH) jumped 7% in the pre-market session on Wednesday after the company said that its Genio Therapy would benefit from the new medicare reimbursement criteria for CY2026.</p><p>The U.S. Centers for Medicare &amp; Medicaid Services (CMS) finalized its CY2026 medicare reimbursement rules on Friday.</p><h2 class="st-heading-2">How Will It Aid Nyxoah?</h2><p>Under the new rule, Hospital Outpatient Department (HOPD) reimbursement for Nyxoah’s Genio hypoglossal nerve stimulation implants for the treatment of Obstructive Sleep Apnea will increase to approximately $45,000 starting in 2026, a 48% rise compared to 2025, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/11/26/3194857/0/en/Nyxoah-s-Genio-Therapy-Receives-Significant-2026-Medicare-Reimbursement-Increases-Under-Final-CMS-Rule.html">said</a>. Ambulatory Surgery Centers (ASC) facility reimbursement, meanwhile, will increase to $42,373, reflecting a 58% increase compared to 2025.</p><p>Nyxoah expects the stronger reimbursement framework to support broader adoption, increase procedural throughput, and expand across Medicare-heavy institutions. Further, the procedure is well-suited for the ASC environment, and the change in rules creates new opportunities for therapy expansion and site-of-service diversification, the company added.</p><h2 class="st-heading-2">Others To Benefit From New Rules</h2><p>The new rules apply to Nyxoah’s peers, too. Earlier this week, Stifel analyst Jonathan Block upgraded Inspire Medical Systems (INSP) to ‘Buy’ from ‘Hold’ while also hiking the price target to $110, up from $100.</p><p>Inspire Medical makes the Inspire V implant to treat obstructive sleep apnea. It is installed in an approximate 60-minute outpatient procedure. According to the Stifel analyst, the company's headwinds are easing following CMS's positive reimbursement revision on Friday.</p><h2 class="st-heading-2">How Did Stocktwits Users React?</h2><p>On Stocktwits, retail sentiment around NYXH fell from ‘bullish’ to ‘neutral’ territory over the past 24 hours while message volume rose from ‘low’ to ‘high’ levels.</p><figure class="image"><img style="aspect-ratio:624/60;" src="data:image/png;base64,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" width="624" height="60" alt="NYXH’s Sentiment Meter and Message Volume as of 7:56 a.m. ET on Nov. 26, 2025 | Source: Stocktwits"><figcaption>NYXH’s Sentiment Meter and Message Volume as of 7:56 a.m. ET on Nov. 26, 2025 | Source: Stocktwits</figcaption></figure><p><a href="https://stocktwits.com/symbol/NYXH">NYXH stock</a> fell 43% this year and by about 44% over the past 12 months.&nbsp;</p><p>Also See: <a href="https://stocktwits.com/news-articles/markets/equity/bytedance-reportedly-tops-chinese-nvidia-chip-buyers-but-now-it-can-t-use-them/cL53FkSREWe">Bytedance Reportedly Tops Chinese Nvidia Chip Buyers – But Now It Can't Use Them</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com</i></p>

Natalie Boller, 63, has a Genio Nyxoah bilateral hypoglossal nerve stimulator implant fitted for obstructive sleep apnoea. Picture date: Wednesday December 4, 2024. (Photo by Lucy North/PA Images via Getty Images)

Nyxoah SA Stock Rises Pre-Market After CMS Raises Reimbursement For Sleep Disorder Therapy

Nyxoah expects the stronger reimbursement framework to support broader adoption, increase procedural throughput, and expand across Medicare-heavy institutions.

Equity

Cantor Fitzgerald Raises Earnings Estimates for Nyxoah

Nyxoah SA (NASDAQ:NYXH - Free Report) - Research analysts at Cantor Fitzgerald boosted their FY2025 earnings estimates for shares of Nyxoah in a report released on Wednesday, November 19th. Cantor...

Nyxoah (NASDAQ:NYXH) Posts Quarterly Earnings Results, Misses Expectations By $0.13 EPS

Nyxoah (NASDAQ:NYXH - Get Free Report) issued its quarterly earnings results on Thursday. The company reported ($0.74) EPS for the quarter, missing analysts' consensus estimates of ($0.60) by...

Nyxoah SA (NYXH) Reports Q3 Loss, Beats Revenue Estimates

Nyxoah (NYXH) delivered earnings and revenue surprises of -21.31% and +18.02%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Enovis (ENOV) Q3 Earnings and Revenues Beat Estimates

Enovis (ENOV) delivered earnings and revenue surprises of +11.94% and +2.41%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

10x Genomics (TXG) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

10x Genomics (TXG) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Nyxoah SA (NYXH) to Report a Decline in Earnings: What to Look Out for

Nyxoah (NYXH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Nyxoah Shares Rise on First U.S. Commercial Use of Genio System

NYXH's first U.S. commercial use of its Genio system signals strong physician demand and sets the stage for broad adoption in sleep apnea care.

Nyxoah SA is a medical technology company, which engages in the development and commercialization of solutions to treat Obstructive Sleep Apnea (OSA). Its solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe OSA. The company was founded by Robert Taub and Adi Mashiach on July 15, 2009, and is headquartered in Mont-Saint-Guibert, Belgium.

Nyxoah SA

3%+ above current levels

Up 0–3%

Flat to down 3%

Down 3%+

The Nasdaq 100 continues to hinge on mega-cap tech and AI strength. With rate expectations shifting and valuations stretched, even a 3% move could signal a bigger trend. Is momentum building, or fading?

NYXH
Nyxoah SA

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest NYXH News

NYXHNyxoah SA